Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.

Sampson, John H; Heimberger, Amy B; Archer, Gary E; Aldape, Kenneth D; Friedman, Allan H; Friedman, Henry S; Gilbert, Mark R; Herndon, James E; McLendon, Roger E; Mitchell, Duane A; Reardon, David A; Sawaya, Raymond; Schmittling, Robert J; Shi, Weiming; Vredenburgh, James J; Bigner, Darell D

Sampson, John H; Heimberger, Amy B; Archer, Gary E; Aldape, Kenneth D; Friedman, Allan H; Friedman, Henry S; Gilbert, Mark R; Herndon, James E; McLendon, Roger E; Mitchell, Duane A; Reardon, David A; Sawaya, Raymond; Schmittling, Robert J; Shi, Weiming; Vredenburgh, James J; Bigner, Darell D.

Affiliation

Sampson JH; Duke University Medical Center, Durham, NC 27710, USA.

J Clin Oncol ; 28(31): 4722-9, 2010 Nov 01.

Article in En | MEDLINE | ID: mdl-20921459

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Brain Neoplasms / Glioblastoma / Cancer Vaccines / ErbB Receptors Type of study: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Country/Region as subject: America do norte Language: En Journal: J Clin Oncol Year: 2010 Document type: Article Affiliation country: Estados Unidos Country of publication: Estados Unidos

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google